Cordis, Cardinal Health’s interventional vascular business, has announced the commercial launch of three new products that further enhance its interventional cardiology product portfolio in Europe, the Middle East, and Africa (EMEA).
The addition of the Cordis RAILWAY Sheathless Access System as well as Ikazuchi Zero and Raiden3, Kaneka’s percutaneous transluminal coronary angioplasty (PTCA) balloon catheters, further strengthen Cordis’ product offering that supports the treatment of patients undergoing percutaneous coronary intervention (PCI) from access and diagnostic to intervention and closure.
Cordis and Cardinal Health will showcase their newly expanded competitive and value-based product and services offering at EUROPCR 2017 from May 16-19 in Paris, France (booth F26).
“Strong results from Cordis innovation programs and new distribution agreements have rapidly strengthened our product offering in interventional cardiology in EMEA,” said Bertrand Deluard, President, Cardinal Health, EMEA.
“These cardiology products nicely complement the drug-eluting stents we launched in EMEA last year and we remain committed to making significant contributions to the healthcare system by delivering value-based products and solutions to our customers and their patients.”
“With the complexity of healthcare today, our customers and their patients require partners who can help them gain access to high quality products and solutions at a reasonable cost,” said David Wilson, President, Cordis.
”With our extensive and growing product offering and business solutions, Cordis, as a Cardinal Health company, remains uniquely positioned to deliver on this promise in EMEA and around the world.”
New Products Featured at EUROPCR 2017